Reimagining Management of Generalized Myasthenia Gravis: A Focus on FcRn Inhibitors

Generalized myasthenia gravis (gMG) is a chronic neuromuscular disorder that results from destruction of the neuromuscular junction by pathogenic autoantibodies, partially through the actions of the neonatal Fc receptor (FcRn). Traditional therapies only partially alleviate the heavy disease burden and episodic exacerbations characteristic of gMG. In recent years, FcRn antagonists have shown great promise across broad gMG populations. Clinicians in collaboration with a multidisciplinary care team must understand the potential benefits of FcRn agonists and update best practices to care for patients with gMG.In this CME Outfitters recorded webcast, expert faculty will discuss the role of FcRn in the pathogenesis of gMG, evaluate the safety and efficacy of FcRn antagonists for the treatment of gMG, and provide expert guidance on how to identify patients with gMG who may be appropriate candidates for treatment with FcRn antagonists. Finally, they will model development of optimized and individualized treatment plans for patients with gMG receiving FcRn antagonists, providing learners with key skills to bring back to clinical practice.Learn More Here